The prostate health index (PHI) is a blood test that more accurately assesses the risk of prostate cancer than a traditional PSA test. The PHI combines three different PSA tests to create one risk ...
To the Editor: In the BARCODE1 study, McHugh et al. (April 10 issue) 1 assessed the use of a polygenic risk score in prostate cancer screening, concluding that more clinically significant cases were ...
CHICAGO — Ten years after major changes in the recommendation for prostate cancer screening, a new analysis finds a sharp increase in advanced and terminal cases of the disease. The study highlights ...
Consider this a PSA about PSA. Prostate cancer is the most common cancer in US men, excluding skin cancer, and the second-leading cause of male cancer deaths, after lung cancer. One in 6 men will be ...
ArteraAI Prostate is now an FDA-regulated software (as a medical device) to estimate long-term outcomes and predict the benefit of hormone therapy for individual patients with localized prostate ...
A urine-based biomarker panel detected prostate cancer in 91% of specimens with a diagnostic accuracy of 78.6% to 85.7%, according to a study published Sept. 2 in eBioMedicine. Led by a team from ...
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." FORMER PRESIDENT JOSEPH R. Biden has been diagnosed with Stage 4 prostate cancer, his office announced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback